Tetsuya Watanabe, Y. Akieda, T. Suzuki
Jun 1, 1993
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Drugs
Abstract
Sparfloxacin is a new synthetic antibacterial quinolone derivative that is characterised by the presence of an amino moiety at position 5 of the oxoquinolone structure, a fluorine atom at both positions 6 and 8 and a 5-dimethyl-piperazinyl moiety at position 7. Sparfloxacin has a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria, including anaerobes (Nakamura et al. 1989), and is also readily absorbed and penetrates well into the various tissues (Kanamaru et al. 1988). We carried out a study to evaluate the efficacy and safety of the drug in the treatment of patients with skin, soft tissue and skin structure infections associated with surgery. 82 patients were treated with oral sparfloxacin in this study: 58 patients received 200mg once daily; 13 patients received 300mg once daily; and 11 received l50mg twice daily. The duration of the treatment was 4 to 12 days. Clinical and bacteriological efficacy was evaluated on the basis of findings observed before and after treatment. The patients consisted of 60 males and 22 females aged 16 to 83 years, including 20 who did not undergo surgery. The total overall clinical efficacy rates in the 82 patients enrolled were 86.6%, with rates of 83.3% for infected atheroma, 84.6% for periproctal abscess, 100% for wound infection, and 84.6% for subcutaneous abscess etc. The clinical efficacy rates classified by daily dose were 87.9% for the group receiving 200mg and 83.3% in those receiving 300mg, and 85.0% in patients who did not undergo surgery (table I). The bacteriological eradication rates for Grampositive, Gram-negative and anaerobic bacteria were 89.2% (74 strains), 96.2% (26· strains) and 100% (23 strains), respectively (table, II); eradication rates of 86.5% in monomicrobial,infection (52 cases) and 93.3% in polymicrobial infection (30 cases) were obtained. Neither objective nor subjective side effects were reported in any of the patients. Abnormal laboratory findings were not found in any of the patients. The MIC of sparfloxacin against H 6 of the 118 strains (98.3%) of 34 species isolated from clinical samples was 1.56 mg/L or lower. In conclusion, sparfloxacin has excellent activity against resistant pathogens and could be a safe and useful oral antimicrobial agent in the treatment of skin and skin structure infections.